Aug. 04--BUCHAREST -- The Romanian Association of International Drug Makers (ARPIM) and the Generic Drug Manufacturers Association in Romania (APMGR) are demanding that an independent audit into the data used by the National Health Insurance House (CNAS) for calculating the amount of the clawback tax be conducted, with the two organizations considering that it is maintained "at at unreasonably high level" in Q2 of this year.
In a press release issued on Tuesday for AGERPRES, the two associations are announcing that the "p" percentage in calculating the clawback tax reached 24pct in Q2 2015, a "relatively constant" level versus the previous quarter, when it was 26pct, and argue that "maintaining the same level for the clawback tax, amid a declining drug consumption by over 10pct, according to Cegedim data, sparks big doubts on how the calculations are made by the CNAS."
"This difference is surprising, because the estimate made by Cegedim had taken into account the fact that the stocks on the market in this quarter were very low, awaiting updated prices. It was natural for this to be found also in the invoices received from the authorities. (...) We believe that conducting an audit into the data (related to the actual drug consumption) used in the calculation of the clawback tax is mandatory. It is the only variant in which we can speak of a sustainable business environment," Calin Galaseanu, ARPIM president, was quoted as saying by the release.
"An independent control over the calculation of the clawback tax and the data used is the only way to correct these serious deficiencies in the application of the clawback tax, given the total lack of transparency of the CNAS towards producers. (.. .) There are signals that companies pay the clawback tax at an almost identical level to their turnover in Q2 2015, which basically means insolvency," says, in his turn, Dragos Damian, APMGR president, according to the same press release.
The two associations consider that "maintaining this system will only lead to losses for both the state, which will be faced with a situation in which it will have to repay money to companies that will challenge it in court, as well as for drug producers, who, due to the huge costs of the clawback tax, will be forced to eliminate even more drugs from the Romanian market, and to postpone major investments in local production facilities."
(c)2015 Agerpres, Bucharest, Romania
Visit Agerpres, Bucharest, Romania at www1.agerpres.ro/english
Distributed by Tribune Content Agency, LLC.
© Tribune Content Agency, source Regional News